Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:50:26 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:VSTM - VERASTEM INC - https://www.verastem.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VSTM - Q1.06.00·6.750.36.67+0.396.21,278.77,84610,3506.36  6.755  6.3611.245  4.0118:50:08Feb 0415 min RT 2¢

Recent Trades - Last 10 of 10350
Time ETExPriceChangeVolume
18:50:08Q6.600.326
18:27:48Q6.750.471
18:16:36Q6.600.321
17:05:51Q6.600.321
16:48:23Q6.73650.456550
16:29:06Q6.740.463
16:10:05Q6.670.391
16:10:05Q6.670.391
16:10:04Q6.670.391
16:10:04Q6.670.391

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 07:30U:VSTMNews ReleaseVerastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
2026-01-12 16:01U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-29 16:01U:VSTMNews ReleaseVerastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
2025-12-15 16:01U:VSTMNews ReleaseVerastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
2025-11-25 07:30U:VSTMNews ReleaseVerastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
2025-11-14 00:41U:VSTMNews ReleaseVerastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-13 16:07U:VSTMNews ReleaseVerastem Oncology Announces Proposed Public Offering of Common Stock
2025-11-05 07:30U:VSTMNews ReleaseVerastem Oncology to Present at Upcoming Investor Conferences
2025-11-04 07:30U:VSTMNews ReleaseVerastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
2025-10-23 16:01U:VSTMNews ReleaseVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
2025-10-23 07:30U:VSTMNews ReleaseVerastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
2025-10-19 04:15U:VSTMNews ReleaseVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
2025-10-07 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-27 07:00U:VSTMNews ReleaseVerastem Oncology to Present at Upcoming Investor Conferences
2025-08-13 16:29U:VSTMNews ReleaseVerastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
2025-08-07 16:05U:VSTMNews ReleaseVerastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
2025-07-29 07:30U:VSTMNews ReleaseVerastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-07-24 07:30U:VSTMNews ReleaseVerastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
2025-07-11 16:12U:VSTMNews ReleaseVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
2025-07-08 08:50U:VSTMNews ReleaseGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies